EOC Pharma Group

EOC Pharma operates as an integrated biopharmaceutical firm with a strategic focus on the oncology sector in China. The company was established in 2010 by Dr. Xiaoming Zou and Xin Ni and operates as a spin-off from the oncology division of Eddingpharm. Dr. Zou, the CEO, brings prior experience from senior roles at Amgen and GlaxoSmithKline, while Mr. Ni, the Chairman, founded Eddingpharm and has over two decades of experience in the Chinese pharmaceutical market.

The company's business model centers on in-licensing promising mid- and late-stage oncology drug candidates from global partners and advancing their development and commercialization for the Chinese market. This strategy allows EOC Pharma to leverage existing ex-China clinical data to expedite the approval process with the National Medical Products Administration (NMPA). The firm complements this in-licensing approach with its own independent R&D centers in Suzhou and Taizhou, which concentrate on early-stage translational medicine and the discovery of new compounds. Revenue is generated through the commercialization of these oncology products upon receiving regulatory approval.

EOC Pharma is building a specialized portfolio targeting breast and gastric cancers, two of the most prevalent cancers in China. Its pipeline includes multiple candidates in various clinical phases. Key assets include Entinostat (EOC103), an oral histone deacetylase (HDAC) inhibitor for breast cancer licensed from Syndax Pharmaceuticals, and Telatinib (EOC315), a VEGF receptor inhibitor for gastric cancer with worldwide rights from ACT Biotech Inc. Other pipeline candidates include EOC202, a soluble LAG-3 fusion protein, and EOC317, an FGFR inhibitor. The company has successfully raised significant capital to fund its clinical trials and operations, including a $32 million Series B in 2017 and a $71 million Series C in 2019, with backing from investors like Sequoia China, Taikang Investment, and Tigermed.

Keywords: oncology, biopharmaceutical, China healthcare, cancer treatment, drug development, clinical trials, in-licensing, breast cancer, gastric cancer, solid tumors, Entinostat, Telatinib, HDAC inhibitor, VEGFR inhibitor, pharmaceutical commercialization, NMPA, immuno-oncology, targeted therapy, Eddingpharm, Xiaoming Zou